3.90%
-2.52%
13.66%
129.45%
85.89%
160.47%
161.22%
AI Spotlight on TARS
Company Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions.Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction.
In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases.Tarsus Pharmaceuticals, Inc.was incorporated in 2016 and is headquartered in Irvine, California.
Market Data
| Last Price | 53.76 |
| Change Percentage | 3.90% |
| Open | 52.25 |
| Previous Close | 51.74 |
| Market Cap ( Millions) | 2055 |
| Volume | 284359 |
| Year High | 57.14 |
| Year Low | 20.08 |
| M A 50 | 50.75 |
| M A 200 | 37.06 |
Financial Ratios
| FCF Yield | -5.47% |
| Dividend Yield | 0.00% |
| ROE | -55.86% |
| Debt / Equity | 30.46% |
| Net Debt / EBIDTA | 82.01% |
| Price To Book | 7.55 |
| Price Earnings Ratio | -13.35 |
| Price To FCF | -18.29 |
| Price To sales | 13.78 |
| EV / EBITDA | -13.29 |
News
- Jan -30 - Tarsus to Participate in Upcoming Investor Conferences
- Jan -14 - Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround
- Jan -13 - Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
- Dec -24 - 4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
- Dec -15 - Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks
- Dec -04 - Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet
- Nov -18 - Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade
- Nov -14 - Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript
- Nov -13 - Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
- Nov -13 - Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
- Nov -07 - Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Nov -06 - Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
- Nov -05 - Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
- Oct -30 - Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains?
- Oct -17 - Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
- Sep -25 - Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
- Sep -20 - Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations
- Aug -28 - Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
- Aug -20 - Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment
- Aug -10 - Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pharmaceutical Products
Expected Growth : 8.5 %
What the company do ?
Tarsus Pharmaceuticals, Inc. develops and commercializes innovative pharmaceutical products, including loteprednol etabonate ophthalmic suspension, for the treatment of ocular inflammation and pain.
Why we expect these perspectives ?
Tarsus Pharmaceuticals, Inc.'s 8.5% growth in Pharmaceutical Products is driven by increasing demand for novel treatments, strategic partnerships, and expanding product portfolios. Additionally, growing investments in R&D, favorable regulatory environments, and rising healthcare expenditure contribute to this growth.
Tarsus Pharmaceuticals, Inc. Products
| Product Range | What is it ? |
|---|---|
| TP-03 | A novel, topical antiparasitic cream for the treatment of Demodex blepharitis, a chronic eyelid disease. |
| TP-04 | A novel, oral, non-steroidal treatment for rosacea, a chronic inflammatory skin condition. |
Tarsus Pharmaceuticals, Inc.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Tarsus Pharmaceuticals, Inc. is moderate due to the presence of alternative treatments and therapies for eye care.
Bargaining Power Of Customers
The bargaining power of customers for Tarsus Pharmaceuticals, Inc. is low due to the lack of negotiating power of individual customers.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Tarsus Pharmaceuticals, Inc. is moderate due to the presence of multiple suppliers for raw materials and equipment.
Threat Of New Entrants
The threat of new entrants for Tarsus Pharmaceuticals, Inc. is high due to the attractiveness of the eye care market and the potential for new companies to enter the market.
Intensity Of Rivalry
The intensity of rivalry for Tarsus Pharmaceuticals, Inc. is high due to the presence of established competitors in the eye care market.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 13.30% |
| Debt Cost | 9.45% |
| Equity Weight | 86.70% |
| Equity Cost | 9.45% |
| WACC | 9.45% |
| Leverage | 15.34% |
Tarsus Pharmaceuticals, Inc. : Quality Control
Tarsus Pharmaceuticals, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CSBR | Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach … |
| DNTH | Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that … |
| TCRX | TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment … |
| KYMR | Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It … |
| ONCT | Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Dianthus Therapeutics
A-Score
1-Year Total Return ->
🥈
Kymera Therapeutics
A-Score
1-Year Total Return ->
🥉
Tarsus Pharmaceuticals
A-Score
1-Year Total Return ->
4
Champions Oncology
A-Score
1-Year Total Return ->
5
Oncternal Therapeutics
A-Score
1-Year Total Return ->
6
